ArticleFrontiers in plant science2024
Molecular farming navigates a complex regulatory landscape.
Article in Frontiers in plant science, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Sustainable production of myoglobin meat protein in plant chloroplasts.Frontiers in plant science · 2026Article
- Beyond Side Effect: Immuno-Ethical Risk Analysis of Animal-Derived Ingredients in Pharmaceuticals.Risk management and healthcare policy · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Molecular farming, the practice of engineering plants to produce recombinant proteins, presents novel challenges and opportunities for domestic markets and international trade. This article explores the multifaceted risks associated with these biotechnological advancements, including public health concerns related to recombinant animal proteins produced in plants, cross-contamination and unintended allergens, and the necessity for stringent identity preservation systems to avoid past failures. On the global stage, the trade of such genetically engineered crops brings about unique regulatory concerns, underscoring the need for internationally harmonized policies and reevaluating existing low-level presence (LLP) thresholds to address unexpected allergens. Moreover, molecular farming ventures into complex religious and ethical territories, particularly affecting communities with strict dietary laws, such as Islamic, Jewish, and those following vegan or vegetarian lifestyles. Addressing these concerns requires a collaborative approach among scientists, regulatory bodies, industry leaders, and religious figures, aiming to foster an inclusive dialogue that navigates the ethical, religious, and environmental implications of integrating animal proteins into plant-based systems. Such efforts are essential for ensuring the responsible development of molecular farming technologies, contributing to a future of sustainable, secure, and inclusive food systems that respect diverse cultural and ethical values.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.